Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program

Parties to Collaborate on a New Generation Study 2, Assessing Whether Investigational Drug CNP520 Can Prevent or Delay the Symptoms of Alzheimer's Disease Clinical Trial is Part of the Generation Program, Which Includes Cognitively Healthy People at Genetic Risk of Developing Alzheimer's Disease Generation Study 2 Aims to Include a Broader High-Risk Population, as Compared to the Ongoing Generation Study 1 44 Million People Globally are Estimated to Have Alzheimer's Disease or a Related Dementia, With One New Case Diagnosed Every Three Seconds(1,2) THOUSAND OAKS, Calif., Nov. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Novartis today announced an expanded collaboration with th...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news